CD8A and neoplasm: While mass spectrometry–based immunopeptidomics is currently the only available technique to provide direct proof of actual neoepitope presentation by HLA molecules, these neoepitopes must be recognizable by CD8+ T cells to trigger an immune attack leading to tumor elimination.